Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation

Figure 1. Cumulative risk of intracranial hemorrhage, gastrointestinal bleeding, and all major bleeding for non-valvular AF (NVAF) patients treated with dabigatran, warfarin or rivaroxaban versus AA before propensity score weighting Patients on dabigatran (solid line) have a lower risk of gastrointestinal bleeding and all major bleeding than those on antiplatelet agents (dotted line). Patients on warfarin (solid line) have a higher risk of intracranial hemorrhage than those on antiplatelet agents (dotted line). Patients on rivaroxaban (solid line) have a similar risk of intracranial hemorrhage, gastrointestinal bleeding and all major bleeding than those on antiplatelet agents (dotted line).

Figure 2. Cumulative risk of intracranial hemorrhage, gastrointestinal bleeding, and all major bleeding for NVAF patients treated with dabigatran, warfarin, or rixaroxaban versus AA after propensity score weighting Patients on dabigatran (solid line) had a lower risk of intracranial hemorrhage, gastrointestinal bleeding, and all major bleeding compared to those on antiplatelet agents (dotted line). Patients on warfarin (solid line) had a lower risk of gastrointestinal bleeding, and a similar risk of intracranial hemorrhage and all major bleeding compared to those on antiplatelet agents (dotted line). Patients on rivaroxabn (solid line) had a lower risk of intracranial hemorrhage, and a similar risk of gastrointestinal bleeding and all major bleeding compared to those on antiplatelet agents (dotted line).

Figure 3. Forest plot of hazard ratio of all major bleeding for NVAF patients taking dabigatran versus aspirin after propensity score weighting Dabigatran was associated with a lower risk of all major bleeding events compared with aspirin in most subgroups. The abbreviations as in Figure 1.

Figure 4. Forest plot of hazard ratio of all major bleeding for NVAF patients taking dabigatran versus P2Y12 inhibitor after propensity score weighting Dabigatran was associated with a lower risk of all major bleeding events compared with P2Y12 inhibitor in most subgroups. The abbreviations as in Figure 1.

Figure 5. Forest plot of hazard ratio of all major bleeding for NVAF patients taking rivaroxaban versus aspirin after propensity score weighting Rivaroxaban was associated with a similar risk of all major bleeding as compared with aspirin users in most subgroups. The abbreviations as in Figure 1.

Figure 6. Forest plot of hazard ratios of all major bleeding for NVAF patients taking rivaroxaban versus P2Y12 inhibitor after propensity score weighting Warfarin was associated with a similar risk of all major bleeding as compared with P2Y12 inhibitor in most subgroups. The abbreviations as in Figure 1.

Figure 7. Forest plot of hazard ratios of all major bleeding for NVAF patients taking warfarin versus aspirin after propensity score weighting Warfarin was associated with a similar risk of all major bleeding as compared with aspirin in most subgroups. The abbreviations as in Figure 1.

Figure 8. Forest plot of hazard ratios of all major bleeding for NVAF patients taking warfarin versus P2Y12 inhibitor after propensity score weighting Warfarin was associated with a similar risk of all major bleeding as compared with P2Y12 inhibitor in most subgroups. The abbreviations as in Figure 1.

Figure 9. Enrollment of patients with NVAF A total of 304,252 new non-valvular atrial fibrillation (NVAF) patients including 6,600 dabigatran (D), 3,167 rivaroxaban (R), 5,338 warfarin (W), and 8,238 antiplatelet agent (AA) users were enrolled in this study from June 1, 2012 to December 31, 2013. Rivaroxaban was enrolled in this study from February 1, 2013 duo to its approval at that day in Taiwan.